Type IV hypersensitivity

53,902views

Type IV hypersensitivity

Foundations

Foundations

Introduction to the immune system
Innate immune system
Complement system
Contracting the immune response and peripheral tolerance
Cytokines
Monoclonal antibodies
Antibody classes
Bacterial structure and functions
B-cell development
B-cell activation, differentiation, and contraction
T-cell development
T-cell activation
B- and T-cell memory
MHC class I and MHC class II molecules
Thymus histology
Cell cycle
Mitosis and meiosis
DNA replication
DNA damage and repair
DNA mutations
Cell membrane
Free radicals and cellular injury
Hypoxia
Necrosis and apoptosis
Inflammation
Crohn disease
Gout
Gout and pseudogout: Pathology review
Inclusion body myopathy
Inflammatory bowel disease: Pathology review
Papulosquamous and inflammatory skin disorders: Pathology review
Myasthenia gravis
Systemic lupus erythematosus
Type I hypersensitivity
Type II hypersensitivity
Type III hypersensitivity
Type IV hypersensitivity
Serum sickness
Anaphylaxis
Graft-versus-host disease
Systemic lupus erythematosus (SLE): Pathology review
Pemphigus vulgaris
Stevens-Johnson syndrome
Rheumatic heart disease
Heart failure: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Body fluid compartments
Movement of water between body compartments
Hyponatremia
Pulmonary edema
Lymphedema
Coagulation (secondary hemostasis)
Platelet plug formation (primary hemostasis)
Erythropoietin
Hemophilia
Coagulation disorders: Pathology review
Platelet disorders: Pathology review
Blood components
Protein C deficiency
Protein S deficiency
Metaplasia and dysplasia
Multiple endocrine neoplasia: Pathology review
Oncogenes and tumor suppressor genes
Amyloidosis
Atrophy, aplasia, and hypoplasia
Environmental and chemical toxicities: Pathology review
Medication overdoses and toxicities: Pathology review
Multiple endocrine neoplasia
Substance misuse and addiction: Clinical
Toxidromes: Clinical
Deep vein thrombosis and pulmonary embolism: Pathology review
Heparin-induced thrombocytopenia
Myocardial infarction
Shock
Arterial disease
Atherosclerosis and arteriosclerosis: Pathology review
Carbohydrates and sugars
Childhood nutrition and obesity: Information for patients and families (The Primary School)
Fat-soluble vitamin deficiency and toxicity: Pathology review
Folate (Vitamin B9) deficiency
Iron deficiency anemia
Osteomalacia and rickets
Vitamin B12 deficiency
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Wernicke-Korsakoff syndrome
Zinc deficiency and protein-energy malnutrition: Pathology review
Burns: Clinical
Burns
Hyperplasia and hypertrophy
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Klinefelter syndrome
Turner syndrome
Angelman syndrome
Prader-Willi syndrome
Fragile X syndrome
DiGeorge syndrome
Phenylketonuria (NORD)
Homocystinuria
Maple syrup urine disease
Disorders of fatty acid metabolism: Pathology review
Ornithine transcarbamylase deficiency
Post-transplant lymphoproliferative disorders (NORD)
Cytomegalovirus infection after transplant (NORD)
Epigenetics
Gene regulation
Independent assortment of genes and linkage
Inheritance patterns
Mendelian genetics and punnett squares
Evolution and natural selection
Antiphospholipid syndrome
Celiac disease
Graves disease
Multiple sclerosis
Diabetes mellitus
Chronic granulomatous disease
Immunodeficiencies: Clinical
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Candida
Mycobacterium tuberculosis (Tuberculosis)
Tuberculosis: Pathology review
Pneumonia: Pathology review
Pneumonia
Salmonella (non-typhoidal)
Viral structure and functions
Hepatitis medications
Herpesvirus medications
Neuraminidase inhibitors
HIV (AIDS)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Integrase and entry inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Protease inhibitors
Vaccinations: Clinical
The flu vaccine: Information for patients and families
Vaccinations

Transcript

Watch video only

Content Reviewers

Having a hypersensitivity means that someone’s immune system has reacted to something in such a way that it ends up damaging them, as opposed to protecting them.

There are four different types of hypersensitivities, and in the fourth type or type 4, the reactions are caused by T lymphocytes, or T cells, and so type IV is also sometimes known as T-cell-mediated hypersensitivity.

T cells are called T cells because they mature in the thymus.

The two types of T cells that cause damage to tissues in type IV hypersensitivity are CD8+ T cells also known as killer T cells or cytotoxic T cells, as well as CD4+ T cells also known as helper T cells.

CD8+ killer T cells do exactly what their name implies - they kill things.

They are like silent assassins of the immune system that go after very specific targets.

In contrast, CD4+ T cells locally release cytokines, which are small proteins that can stimulate or inhibit other cells.

So CD4+ T cells act like little army generals coordinating immune cells around them.

But both CD8+ and CD4+ cells start off as naive cells because their T cell receptor or TCR has not yet bound to their target antigen - which is that specific molecule it can bind to.

Alright so let’s play out a scenario. Let’s say someone’s skin brushes up against poison ivy, and gets the molecule urushiol all over.

That molecule’s small enough to quickly make it’s way through the epidermis to the dermis, which is where it might combine with small proteins, it then might get picked up by a langerhans cell also known as a dendritic cell, which is a type of antigen-presenting immune cell.

The dendritic cell then takes it to the nearest lymph node - the draining lymph node, where it presents the antigen on its surface using a MHC class II molecule, which is basically a serving platter for CD4+ T cells to come check out.

If a TH cell recognizes the antigen, it binds to the MHC class II molecule using its T cell receptor, as well as CD4, which is a co-receptor and this is why it’s called a CD4+ T cell.

At this point the CD4+ or helper T cell will also express a CD28 protein which will bind to the B7 protein on the surface of the dendritic cell.

Once it binds to the TCR and the CD28 protein, the dendritic cell releases interleukin 12, a cytokine, or signaling molecule, that tells the naive CD4+ T cell to mature and differentiate into a type 1 helper T cell, or a TH1 cell - a sort of coming of age moment.

At this point, the CD4+ T cell is no longer consider naive, instead it’s an effector cell, that’s able to release the cytokine IL-2, which helps both it and other T cells in the area proliferate, as well as interferon gamma, which activates phagocytes like macrophages and creates more TH1 cells.

Those activated macrophages release proinflammatory cytokines like tumor necrosis factor, IL-1, and IL-6, which cause leakiness in the endothelial barriers and allows more immune cells into the area, all of which leads to local swelling or edema, redness, and warmth as well as systemic symptoms like a fever.

Activated macrophages will also secrete lysosomal enzymes, complement components, and reactive oxygen species into the exposed area, which damages tissue.

Key Takeaways

Type IV hypersensitivity is a type of delayed-type immune response, in which the immune system responds to an antigen several hours or days after exposure. It is also known as cell-mediated hypersensitivity because tissue damage involves T cells. This can be via either CD4+ T helper cells, which help coordinate the attack, or CD8+ killer or cytotoxic T cells, which directly destroy host cells. Examples include contact dermatitis, poison ivy, tuberculin skin test, and certain drug reactions, such as allopurinol. Treatment options for Type IV hypersensitivity may include medications like corticosteroids and avoiding exposure to the triggering antigen.